



## Genemed Synthesis, Inc.

6203 Wood Lake Center Dr., Bldg. 2, San Antonio, TX 78244, USA  
**Toll free** (800) 344-5337; **Phone:** (210) 745-5988; **Fax** (210) 745-5992  
**Email:** [info@genemedsyn.com](mailto:info@genemedsyn.com), **Website:** [www.genemedsyn.com](http://www.genemedsyn.com)

<b>Name</b>	<b>Enfuvirtide (T-20)</b>
<b>Cat #</b>	PP-1230
<b>Size</b>	1 mg and bulk custom packages
<b>CAS#</b>	159519-65-0
<b>Mol. Mass</b>	4492.1
<b>Formula</b>	C202H298N50O64
<b>Sequence</b>	Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH <sub>2</sub>
<b>Purity</b>	>95%

Enfuvirtide is a 36 residue synthetic peptide that inhibits HIV-1 fusion with CD4 cells. N-terminal acetylated C-terminal amide. It is a peptide mimetic of an essential region within viral envelope glycoprotein gp41 that functions by blocking gp41 structural rearrangements at a transitional pre-fusion conformation.

Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).

Enfuvirtide therapy costs an estimated USD\$25,000 per year in the United States. Its cost and inconvenient dosing regimen are factors behind its use as a reserve, for "salvage" therapy in patients with multi-drug resistant HIV

